Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial

Journal of Diabetes and its Complications

Volumn 17, Issue 6, 2003, Pages 314-322

  Abraira, Carlos ^a   Duckworth, William ^b   McCarren, Madeline ^c   Emanuele, Nicholas ^d   Arca, Danielle ^a   Reda, Domenic ^c   Henderson, William ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b CARL T HAYDEN VA MEDICAL CENTER   (United States)

^c Hines VA Coop Studs Prog C   (United States)

^d HINES VA HOSPITAL   (United States)

Author keywords

Diabetes mellitus type 2; Glycemic control; Hemoglobin A1c; Veterans Affairs Diabetes Trial

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOGEN; GLIMEPIRIDE; HEMOGLOBIN A1C; INSULIN; LIPID; METFORMIN; PLASMINOGEN ACTIVATOR INHIBITOR; ROSIGLITAZONE;

ADULT; AGED; AMPUTATION; ARTICLE; BLOOD PRESSURE REGULATION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIET; DYSLIPIDEMIA; ELECTROENCEPHALOGRAM; EYE PHOTOGRAPHY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSURIA; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPOGLYCEMIA; KETONURIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT EDUCATION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; VISUAL IMPAIRMENT;

EID: 0142199812     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8727(02)00277-5     Document Type: Article

References (37)

1. Abraira C., Colwell J., Nuttall F., Emanuele N., Comstock J., Levin S., Sawin C., Silbert C. A critical issue: intensive insulin treatment and macrovascular disease. Diabetes Care. 21:1998;669-671.
2. Abraira C., Colwell J., Nuttall F.Q., Sawin C.T., Nagel N.J., Comstock J.P., Emanuele N.V., Levin S.R., Henderson W., Lee H.S. Results of the feasibility trial. Diabetes Care. 18:1995;1113-1123.
3. Abraira C., Colwell J., Nuttall F., Sawin C., Henderson W., Comstock J., Emanuele N., Levin S., Pacold I., Lee H.S. Cardiovascular events and correlates in the VA Feasibility Trial (VACSDM). Archives of Internal Medicine. 157:1997;181-188.
4. Consensus statement on guidelines for glycemic control. Endocrine Practice. 8(Suppl. 1):2002;5-11.
5. Clinical practice recommendations 2002. Diabetes Care. 25(Suppl. 1):2000;S33-S49.
6. Barrett-Connor E. Does hyperglycemia really cause coronary artery heart disease? Diabetes Care. 20:1997;1620-1623.
7. Camacho P., Pitale S., Abraira C. Beneficial and detrimental effects of intensive glycemic control, with emphasis on type 2 diabetes mellitus. Drugs & Aging. 17(6):2000;463-476.
8. Chang J., Hoke C., Ettinger B., Penerian G. Evaluation and interference study of hemoglobin A1c measured by turbidometric inhibition immunoassay. American Journal of Clinical Pathology. 109:1998;274-278.
9. DeClerk P.J., Alessi M.-C., Verstreken M., Kruithof E.K.O., Juhan-Vague I., Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood. 71:1988;220-225.
10. Department of Veterans Affairs, Office of Quality and Performance. Management of diabetes mellitus in primary care [Link: Annotations]. Available at: http://www.oqp.med.va.gov/cpg/DM/dm_cpg/content/ModG/modG_fr.htm . Accessed October 2002.
11. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine. 329:1993;977-986.
12. Duckworth W., McCarren M., Abraira C. The Department of Veterans Affairs Diabetes Trial. Diabetes Care. 24:2001;942-945.
13. Duckworth W., Saudek C., Giobbie-Hurder A., Henderson W.G., Henry R.R., Kelley D.E., Edelman S.V., Zieve F.J., Adler R.A., Anderson R.J., Hamilton B.P., Donner T.W., Kirkamn S., Morgan N.A. The Veterans Affairs Implantable Insulin Group study: effect on cardiovascular risk factors. Diabetes Care. 21:1998;1596-1602.
14. Eastman R.C., Javitt J.C., Herman W.H., Dasbach E.J., Copley-Merriman C., Maier W., Dong F., Manninen D., Zbrozek A.S., Kotsanos J., Garfield S.A., Harris M. Model of complications of NIDDM II: analysis of the health benefits and cost effectiveness of treating NIDDM. Diabetes Care. 20:1997;735-744.
15. Aspirin effects on mortality and morbidity in patients with diabetes mellitus: early treatment diabetic retinopathy study report 14. JAMA, Journal of the American Medical Association. 268:1992;1292-1300.
16. Ferris F.L. How effective are treatments for diabetic retinopathy? JAMA, Journal of the American Medical Association. 269:1993;1290-1291.
17. Geiss S., Herman W.H., Smith P.J. Mortality in non-insulin-dependent diabetes. Harris M. Diabetes in America. 2nd ed. 1995;133-155 National Diabetes Data Group, National Institutes of Health, Bethesda, MD. NIH Publication No. 95-1468.
18. Gold A., MacLeod K., Deary I., Frier B. Hypoglycemia-induced cognitive dysfunction in diabetes mellitus: effect of hypoglycemia unawareness. Physiology & Behavior. 58:1995;501-511.
19. Gold A.E., Deary I.J., Frier B.M. Hypoglycaemia and non-cognitive aspects of psychological function in insulin-dependent (type 1) diabetes mellitus (IDDM). Diabetic Medicine. 14:1997;111-118.
20. Kannel W.B., D'Agostino R.B., Wilson P.W.F., Belanger A.J., Gagnon D.R. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. American Heart Journal. 120:1990;672-676.
21. Klein R., Klein B.E.K. Vision disorders in diabetes. Harris M. Diabetes in America. 2nd ed. 1995;293-338 National Diabetes Data Group, National Institutes of Health, Bethesda, MD. NIH Publication No. 95-1468.
22. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes Care. 48:1999;937-942.
23. Levin S.R., Coburn J.W., Abraira C., Henderson W.G., Colwell J.A., Emanuele N.V., Nuttall F.Q., Sawin C.T., Comstock J.P., Silbert C.K. The effect of intensive glycemic control on microalbuminuria in type 2 diabetes mellitus. Diabetes Care. 23:2000;1478-1485.
24. Lezak M. Orientation and attention. Neuropsychological assessment. 3rd ed. 1995;357-381 Oxford University Press, New York.
25. Meigs J., Singer D., Sullivan L., Dukes K., D'Agostino R., Nathan D., Wagner E., Kaplan S., Greenfield S. Metabolic control and prevalent cardiovascular disease in non-insulin-dependent diabetes mellitus (NIDDM): the NIDDM patient outcomes research team. American Journal of Medicine. 102:1997;38-47.
26. National Committee for Quality Assurance & American Diabetes Association. Diabetes Physician Recognition Program. Available at: Accessed October 2002.
27. Pyorala K., Pedersen T.R., Kjekshus J., Faergeman O., Olsson A.G., Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 20:1997;614-620. published erratum appears in Diabetes Care, 20 (1997) 1048.
28. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M.O., Wun C.-C., Davis B.R., Braunwald E. Cholesterol and recurrent events trial investigators: the effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New England Journal of Medicine. 335:1996;1001-1009.
29. Shichiri M., Ohkubo Y., Kishikawa H., Wake N. Long term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 23:2000;B21-B29.
30. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., Hadden D., Turner R.C., Holmann R.R. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, British Medical Journal. 321:2000;405-412.
31. Swaim W.R., Feders M.B. Fibrinogen assay. Clinical Chemistry. 13:1967;1026-1028.
32. Turner R., Cull C., Holman R. The effect of improved metabolic control on complications of NIDDM: UKPDS 17. Annals of Internal Medicine. 124(1, Pt. 2):1996;136-145.
33. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risks of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 352:1998;837-853.
34. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ, British Medical Journal. 317:1998;703-713.
35. Vijan S., Hofer T., Hayward R. Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Annals of Internal Medicine. 127:1997;788-795.
36. von Clauss A. Gerinnungsphysiologische schnellmethode zur bestimmung des fibrinogens. Acta Haematologica. 17:1957;237-246.
37. Zhang Q., Safford M., Ottenweller J., Hawley G., Repke D., Burgess J., Dhar S., Cheng H., Naito H., Pogach L. Performance status of health care facilities changes with risk adjustment of HbA1c. Diabetes Care. 23:2000;919-927.